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Abstract Two tandem cassettes, one containing the telomerase
reverse transcriptase gene (hTERT) promoter upstream of a
constitutively activated form of heat shock transcription factor
1 (cHSF1) and followed by the other containing the heat shock
protein 70B (hsp70B) promoter (HSE) upstream of the cytosine
deaminase (CD) gene, could greatly enhance the e⁄ciency of
CD gene therapy while retaining tumor speci¢city in vitro and in
vivo. This hTERT-cHSF1/HSE promoter could restrict gene
expression in tumor cells and was about 1.5^3-fold more potent
than the cytomegalovirus (CMV) promoter. hTERT-cHSF1/
HSE-CD transfection led to tumor cells more sensitive to 5-£u-
orocytosine compared with hTERT-CD and its toxicity was
comparable to that of CMV-CD. Besides enhancement of pro-
moter activity, cHSF1 overexpression itself could enhance the
bystander e¡ect of CD gene therapy that could be reversed by
anti-Fas antibody. This system also led to activation of stress-
related genes such as hsp70 in tumor cells, which in the presence
of cell killing by the cytotoxic gene is a highly immunostimula-
tory event. Furthermore, a more potent anti-tumor e¡ect of
hTERT-cHSF1/HSE-CD was observed in nude mice inoculated
with Bcap37 cells. No obvious activity of the hTERT-cHSF1/
HSE promoter was observed in normal tissues after intravenous
administration. These results indicate that the hTERT-cHSF1/
HSE promoter is highly tumor-speci¢c and strong with potential
application in targeted gene therapy, and therefore may be use-
ful for construction of vectors for systemic therapy.
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1. Introduction
Tumor targeting is crucial to achieve successful e¡ects in
suicide gene therapy because the expression of the therapeutic
gene may cause toxicity in normal tissues with systemic ad-
ministration. It can be achieved by targeting of the delivery
vector or restriction of expression of the therapeutic gene at
the transcriptional level. Early clinical trials have demon-
strated that, even using replicating vectors, the e⁄ciency of
gene delivery to tumors is generally very low [1]. It has been
shown that the inclusion of tissue-speci¢c, inducible or even
potentially tumor-speci¢c transcriptional elements can be very
e¡ective at targeting gene expression to tumor cells of several
di¡erent histological types [2].
Currently used tumor-speci¢c promoters include the tyrosi-
nase gene promoter in melanomas [3], the carcinoembryonic
antigen promoter in colorectal and lung cancer cells [4], the
MUC1 promoter in breast cancer [5], and the E2F promoter
in cancers that carry a defective retinoblastoma gene [6].
Nevertheless, although several reports suggest that relatively
tumor-speci¢c transgene expression is possible using these
promoters, they also reveal several limitations. First, most
of these promoters are limited to speci¢c tumor histologies
and cannot be used universally in tumors of various origins.
To overcome this limitation, the telomerase reverse transcrip-
tase (hTERT) promoter has recently been used to restrict gene
expression to various tumor cells, because approximately 90%
of tumors have telomerase activity, whereas most normal cells
do not express telomerase [7]. Second, most of these pro-
moters are much weaker than commonly used viral promoters
such as the cytomegalovirus (CMV) early promoter, and the
simian virus 40 (SV40) early promoter [8]. Consequently, their
use is hampered by the problem of low expression. Gene ex-
pression driven by the hTERT promoter is also much lower
than that driven by the CMV or SV40 promoter [9,10] and
needs further improvement.
Previous researchers have induced tumor-speci¢c death by
selective expression of the cytosine deaminase (CD) or the
herpes simplex virus thymidine kinase genes in tumor cells.
However, few reports have demonstrated su⁄cient anti-tumor
e¡ects, even when tumor cells were introduced with speci¢c
promoter^suicide chimera genes in vivo by adenovirus (Ad),
the most e⁄cient vector for introducing foreign genes into
target cells [11,12]. It is conceivable that low activity of cell
type-speci¢c promoters is not enough to induce su⁄cient drug
sensitivity in vivo and expression of the suicide gene at a
higher level is necessary for complete remission of tumors
[13]. Therefore, we devised a transcriptionally regulating pro-
moter system derived from the hTERT promoter which has
broad tumor speci¢city with relatively low activity, to enhance
tumor-speci¢c CD gene therapy. In this promoter system, the
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heat shock protein 70B (hsp70B) promoter (HSE) was used to
initiate CD expression, following another tandem cassette
containing a constitutively activated form of heat shock tran-
scription factor 1 (cHSF1) [14] which could activate HSE in
the absence of stress, under the control of the tumor-targeting
hTERT promoter.
Here, we demonstrate that this promoter system signi¢-
cantly enhances tumor-speci¢c suicide gene therapy in vitro
and in vivo and may be useful for systemic therapy.
2. Materials and methods
2.1. Cell lines
Human hepatocarcinoma cell lines Hep3B and HepG2, human cer-
vical cancer cell line HeLa, human breast cancer cell line MCF-7,
human colorectal cancer cell lines SW620 and HCT-116BG, human
normal amnion cells WISH, and human fetal lung ¢broblasts HFL-1
were purchased from ATCC (American Tissue Culture Collection,
Rockville, MD, USA). Human breast cancer cell line Bcap37 was
purchased from Shanghai Cell Collection and grown in RPMI 1640
supplemented with 10% fetal calf serum (Gibco BRL, Grand Island,
NY, USA), 4 mM glutamine, 50 U/ml penicillin and 50 Wg/ml strep-
tomycin. Other cell lines were cultured in Dulbecco’s modi¢ed Eagle’s
medium (DMEM; Gibco BRL) supplemented with 10% heat-inacti-
vated fetal calf serum.
2.2. Plasmids
The core hTERT promoter (3378/+78 bp) was a gift from Dr.
Bingliang Fang (University of Texas M.D. Anderson Cancer Center,
Houston, TX, USA) [9]. HSE and cHSF1 with a deletion between
amino acid positions 202^316 of wild-type HSF1 are described in our
previous work [14]. cHSF1 was cloned downstream of the hTERT
promoter and followed by another cassette containing the indicated
gene under the control of HSE. This promoter system is represented
as hTERT-cHSF1/HSE. To assess promoter strengths, plasmids were
constructed using standard techniques such that di¡erent promoters
(CMV, hTERT, or hTERT-cHSF1/HSE) were placed upstream of
either the luciferase gene in the pGL3-Basic vector (Promega, Madi-
son, WI, USA) or the CD gene in the pcDNA3 plasmid (Invitrogen,
Carlsbad, CA, USA).
2.3. Luciferase assay
Cells mentioned above were seeded in 24-well plates at a density of
105 cells/well. The next day, cells were transfected with 150 ng of
luciferase reporter plasmid and 20 ng of pCMW-L-gal using Lipofect-
amine reagent (Life Technologies, Grand Island, NY, USA) according
to the manufacturer’s instructions. After transfection for 6 h, the
mixture was removed, and the cells were incubated under standard
conditions. Luciferase assays were performed 48 h later using a Lu-
ciferase Assay System Freezer Pack Kit (Promega) and a luminome-
ter, the values being normalized in relation to protein concentration.
Internal normalization of the transfection e⁄cacy was performed us-
ing a Luminescent Detection Kit to detect L-galactosidase (BD Bio-
sciences Clontech, Palo Alto, CA, USA).
2.4. Reverse transcriptase polymerase chain reaction (RT-PCR)
Total cellular RNA was isolated using TRIzol reagent (Life Tech-
nologies) according to the manufacturer’s protocol. RT-PCR was
performed with total RNA (2 Wg) using the First Strand RT-PCR
Kit (Stratagene, La Jolla, CA, USA). A cDNA equivalent of 1 ng
RNA was ampli¢ed by PCR using primers speci¢c for the target
genes. The thermal cycles were: 94‡C for 1 min, 50‡C for 1 min,
72‡C for 2.5 min for 30 cycles for CD (1.3 kb), 94‡C for 1 min,
51‡C for 1 min, 72‡C for 3.5 min for 30 cycles for hsp70 (2.1 kb),
94‡C for 1 min, 55‡C for 1 min, 72‡C for 2 min for 30 cycles for
cHSF1 (1.2 kb). The primer sets used were as follows: CD, ATGTC-
GAATAACGCTTTACAAAC (forward) and TCAACGTTTG-
TAATCGATGGCT (reverse); hsp70, ATGTCGGTGGTGGGCA-
TAGA (forward) and GGTCGTTCTTCAGATTCCTG (reverse);
cHSF1, CGGAATTCCCTTGCTCGAGATGGATCTGCC (forward)
and GGAAGATCTCTAGGAGACAGTGGGGTCC (reverse). The
ampli¢ed products were fractionated on a 1% agarose gel containing
0.5 mg/ml ethidium bromide and DNA patterns were visualized under
UV light.
2.5. In vitro cytotoxic assays
Cells were plated in 24-well plates at a density of 105 cells/well and
transfected with 1 Wg of the appropriate plasmid using Lipofectamine.
Twenty-four hours after transfection, the culture medium was
changed to fresh medium containing various concentrations of 5-£uo-
rocytosine (5-FC; 0, 10, 50, 100, 500, 1000 and 5000 WM; Sigma, St.
Louis, MO, USA). After 5 days of incubation, plates were counted for
living cells using trypan blue exclusion cell counting to assess the
levels of cell survival [15]. Cell viability in wells without 5-FC was
considered 100%. The 50% growth inhibitory concentration (IC50) of
5-FC was calculated using a curve-¢tting parameter, and the results
are represented as the meansTS.D. from three independent experi-
ments.
2.6. Establishment of stable cell lines
Bcap37 cells were transfected with CMV-CD. G418 (100 Wg/ml,
Gibco) was added to the culture medium to select the transfected cells
after 48 h incubation. The selection was continued for 14 days and the
G418-resistant colonies were isolated and propagated under selection
(100 Wg/ml G418), which was designated Bcap37/CMV-CD.
2.7. Adenovirus generation, puri¢cation and titration
Recombinant Ad vector alone (Ad) or that containing cHSF1 (Ad-
cHSF1) was respectively generated by cotransfection of low-passage
293 cells with shuttle plasmid pCA13 or pCA13-cHSF1 and adenovi-
ral packaging vector pBHGE3 (Microbix Biosystems, Toronto, ON,
Canada). Transfections were performed using E¡ectene1 (Qiagen)
according to the manufacturer’s protocol. Individual plaques pro-
duced from recombination events were isolated and validated for
the presence of the cHSF1 gene and absence of the adenoviral E1
gene (wild-type) by PCR. Appropriately validated plaques were puri-
¢ed by two subsequent passages through 293 cells. The ¢nal viral
stock isolated was again veri¢ed by PCR. Quantities of Ad or Ad-
cHSF1 suitable for in vitro studies were produced by infecting 293
cells with validated viral stock as described above, puri¢ed by cesium
chloride gradient ultracentrifugation, and dialysis. The preparation of
Ad or Ad-cHSF1 was titrated by plaque assay using 293 cells.
2.8. Experiments in nude mice
Bcap37 cells (2U106) suspended in 100 Wl of serum-free DMEM
were inoculated subcutaneously and bilaterally into female BALB/c
nu/nu nude mice 4^6 weeks old. After 10 days, when most of the
tumors had reached 3^4 mm in diameter, the mice were randomly
divided into four groups: control, hTERT-CD, CMV-CD and
hTERT-cHSF1/HSE-CD, and intratumoral Lipofectamine-mediated
transfer of these vectors was performed three times (days 1, 4, and
8). 5-FC (250 mg/kg) was simultaneously injected i.p. twice a day for
14 consecutive days. Every 4 days after the beginning of the injection,
tumor sizes were measured for 5 consecutive weeks. The tumor vol-
umes (mm3) were calculated as lengthUwidth2/2. All animal experi-
ments were done with the approval of the Animal Research Commit-
tee at the Institute of Biochemistry and Cell Biology, Chinese
Academy of Sciences.
2.9. In vivo gene expression assay
Plasmid DNA (pGL3-Basic, hTERT-CD, CMV-CD or hTERT-
cHSF1/HSE-CD) was delivered into mouse organs by the hydrody-
namics method [16]. Four to six BALB/c female mice were used in
each group. Twenty micrograms of DNA in 1.6 ml saline was injected
via the tail vein in a time range of 6^7 s. Eight hours later mice were
killed and liver, lung, spleen, heart and kidney were extracted. One
milliliter of lysis bu¡er (0.1 M Tris^HCl, 2 mM EDTA and 0.1%
Triton X-100, pH 7.8) was added to the whole organ for kidney,
spleen, lung and heart. For liver, the same volume of lysis bu¡er
was added to a piece of liver with a wet weight of approximately
200 mg. Samples (0.3 ml) were centrifuged at 14 000 rpm for 10 min
at 4‡C and luciferase activity was measured in concentrated or diluted
supernatants.
2.10. Statistics
Data are expressed as meanTS.D. values. Student’s t-test was ap-
plied to analyze the relationship between the di¡erent variables. Sta-
tistical signi¢cance was taken at P6 0.05.
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3. Results
3.1. In vitro comparison of promoter activity
cHSF1 could constitutively enhance HSE-mediated reporter
gene expression in the absence of heat stress [14]. In this
study, a 378-bp hTERT core promoter controlling cHSF1
expression was followed by a HSE-mediated expression cas-
sette to construct the hTERT-cHSF1/HSE promoter system
(Fig. 1A). The activity of di¡erent promoters (CMV, hTERT,
hTERT-cHSF1/HSE) was assessed in seven cancer cell lines of
various origins and two normal cell lines by the luciferase
assay (Fig. 1B). The results show that hTERT promoter ac-
tivity was signi¢cantly higher in tumor cells than in normal
cells (P6 0.01) where its activity was not signi¢cantly di¡erent
from that of pGL3-Basic. Despite its high tumor speci¢city,
hTERT promoter activity was 10^30-fold less than CMV pro-
moter activity in tumor cells. However, the hTERT-cHSF1/
HSE promoter was about 1.5^3-fold more potent than the
CMV promoter in tumor cell lines and remained very weakly
active in normal cell lines. These results together demonstrate
that the hTERT-cHSF1/HSE promoter is much stronger than
the hTERT promoter in various tumor cell lines and could
restrict gene expression speci¢cally to tumor cells.
3.2. Enhanced tumor-speci¢c suicide e¡ect by the
hTERT-cHSF1/HSE promoter in vitro
To test the e⁄cacy of the hTERT-cHSF1/HSE promoter
for selective tumor gene therapy, plasmids carrying the CD
gene under the control of the CMV, hTERT or hTERT-
cHSF1/HSE promoter were transfected into tumor cell lines
Bcap37 or SW620 and normal cell lines HFL-1 or WISH. To
con¢rm the operation of the hTERT-cHSF1/HSE promoter at
the transcriptional level, RT-PCR was used to detect expres-
sion of the transgenes 48 h after transfection (Fig. 2). Strong
mRNA for CD was detected in both tumor and normal cells
after CMV-CD transfection, whereas it was very low or un-
detectable in normal cells after hTERT-CD or hTERT-
cHSF1/HSE-CD transfection. Following the appearance of
mRNA for cHSF1 in tumor cells transfected with hTERT-
cHSF1/HSE-CD, a much higher level of mRNA for CD
was detected than the hTERT-CD-transfected ones. hTERT-
cHSF1/HSE-CD transfection also led to enhanced tumor-spe-
ci¢c expression of hsp70, which was previously shown to have
very potent immunostimulatory properties in anti-tumor vac-
cination settings.
These data con¢rm that the hTERT-cHSF1/HSE promoter
enhances tumor-speci¢c therapeutic gene expression at the
transcriptional level and can induce endogenous heat shock
gene expression. The latter induction will provide e¡ective
adjuvant functions for immunostimulation. It indicates that
such a strategy would have an additional therapeutic advan-
tage in vivo.
To analyze the 5-FC sensitivity of di¡erent promoters, the
cells mentioned above were cultured in medium containing
various concentrations of 5-FC for 5 days. The IC50 values
are shown in Table 1. The results show that CMV-CD had
signi¢cant toxicity in both tumor and normal cell lines.
hTERT-CD only gave relatively low toxicity in Bcap37 and
SW620 cells, but not in HFL-1 and WISH cells. hTERT-
cHSF1/HSE-CD transfection speci¢cally rendered tumor cell
lines Bcap37 and SW620 about 23-fold more sensitive to 5-FC
compared with hTERT-CD (P6 0.0001) and its toxicity was
comparable to that of CMV-CD.
3.3. E¡ect of cHSF1 in the enhancement of the bystander e¡ect
in vitro
To test whether this enhancement of 5-FC sensitivity was
Fig. 1. In vitro promoter activity assay. A: The hTERT-cHSF1/
HSE promoter sketch. PA, poly(A). B: Assessment of promoter ac-
tivity in tumor or normal cell lines. Cells were transfected with lu-
ciferase reporter plasmid containing the luciferase gene under the
control of di¡erent promoters (hTERT, CMV, hTERT-cHSF1/
HSE). Luciferase assays were performed 48 h later. The values
(meanTS.D. for four assays) are represented as relative light units/
mg of protein. The cells transfected by pGL3-Basic without en-
hancer/promoter were used as a negative control.
Fig. 2. The hTERT-cHSF1/HSE promoter is operative at the transcriptional level. Cell lines (normal cell lines: 1, HFL-1 and 2, WISH; tumor
cell lines: 3, Bcap37 and 4, SW620) were transfected with plasmids containing the CD gene under the control of di¡erent promoters (CMV,
hTERT, hTERT-cHSF1/HSE). Cells were harvested 48 h later and the mRNA expression of the CD or cHSF1 transgenes and of endogenous
hsp70 were examined by RT-PCR.
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dependent on promoter activation only or cHSF1 itself also
had some e¡ect, we examined the e¡ect of cHSF1 overexpres-
sion on non-heat-inducible CMV promoter. To obtain CD
gene expression in all cells tested, the stable cell line
Bcap37/CMV-CD was established and infected with Ad-
cHSF1. The results show that Ad-cHSF1 infection decreased
the IC50 of Bcap37/CMV-CD by 10 times (Fig. 3) while Ad
infection had no such e¡ect, so it was cHSF1 expression that
made Bcap37/CMV-CD cells more sensitive to CD/5-FC gene
therapy. It has been reported that cHSF1 overexpression
could sensitize tumor cells to Fas killing [17]. Other reports
have revealed that 5-£uorouracil (5-FU) induced apoptosis in
vitro via the activation of the CD95/CD95L system [18]. To
investigate whether the Fas apoptosis pathway was involved
in the decrease of IC50 by cHSF1 overexpression, anti-Fas
antibody which neutralized the Fas^FasL interaction, or
non-immune IgG as a negative control, was added to the
medium before treatment with 5-FC. IC50 values in anti-Fas
antibody-treated Bcap37/CMV-CD cells returned from 16T 2
WM to 301T 18 WM, suggesting that this blocking antibody
protected cells against additional Fas-induced apoptosis in the
CMV-CD and Ad-cHSF1 combined treatment group. IC50
values in negative control cells were not changed by such
treatment.
3.4. Enhancement of suicide gene therapy by the
hTERT-cHSF1/HSE promoter in vivo
On the basis of the above-described in vitro studies, we
applied this promoter system for suicide gene therapy in
vivo. Di¡erent vectors (CMV-CD, hTERT-CD, or hTERT-
cHSF1/HSE-CD) were transfected by the Lipofectamine re-
agent in nude mice subcutaneously implanted with Bcap37
cells. Fig. 4 shows growth curves of implanted tumors. After
5-FC treatment for 14 days, the control group without gene
transfer showed a continuous increase in tumor size, while the
other three groups all showed suppression of tumor growth.
hTERT-cHSF1/HSE-CD led to a substantial suppression of
tumor growth which was more e¡ective than that of CMV-
CD (P6 0.05).
3.5. Promoter activity assay in normal tissues
To test the speci¢city of the hTERT-cHSF1/HSE promoter
in vivo, we studied the activity of di¡erent promoters in or-
gans other than tumor tissue. Transgene expression using the
hydrodynamics-based gene transfer method has been de-
scribed in lung, spleen, heart, and kidney [16]. In this study,
mice were injected via the tail vein with luciferase gene under
the control of di¡erent promoters (CMV, hTERT, or hTERT-
cHSF1/HSE). Eight hours later, the organs mentioned above
Table 1
5-FC sensitivity of cells transfected with plasmids containing the CD gene under the control of di¡erent promoters (hTERT, CMV, hTERT-
cHSF1/HSE)
Cell line IC50 of 5-FC (WM)a
CMV-CD hTERT-CD hTERT-cHSF1/HSE-CD
HFL-1 195T 5 22 387T 2 132 27 035T3 017
WISH 118T 11 27 386T 3 321 24 130T2 809
Bcap37 295T 24 3 427T 259 143T36*
SW620 358T 47 4 135T 301 176T16*
*P6 0.0001 compared with the IC50 of 5-FC in the same cell line transfected with hTERT-CD.
aIn vitro cytotoxic assays were performed as described in Section 2. The results are represented as meansTS.D. from three independent experi-
ments.
Fig. 3. E¡ect of cHSF1 in the enhancement of the bystander e¡ect
in vitro. Cells were plated in 24-well plates at a density of 105 cells/
well and infected with Ad or Ad-cHSF1 at a multiplicity of infec-
tion of 50. Twenty-four hours later, cells were treated with various
concentrations of 5-FC for 5 days in the presence or absence of
anti-Fas antibody (1:200). Cell survival was assayed as described in
Section 2. Signi¢cance is de¢ned as **P6 0.01 compared with
Bcap37/CMV-CD cells infected with Ad. The values (meanTS.D.
for four assays) are represented as IC50 of 5-FC (WM).
Fig. 4. In vivo therapeutic e¡ect of CD gene driven by di¡erent
promoters. Ten days after inoculation when the tumor diameters
had reached 3^4 mm, 5-FC (250 mg/kg) was injected i.p. twice a
day for 14 consecutive days. Tumor volume was measured every 4
days for 5 weeks and calculated as lengthUwidth2/2. Each data
point represents the meanTS.D. of eight samples. Signi¢cant sup-
pression of tumor growth was observed after treatment with 5-FC
in the hTERT-cHSF1/HSE-CD group compared with the CMV-CD
group (P6 0.05, n=8).
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were extracted and analyzed for luciferase activity. Much low-
er levels of expression were observed with the hTERT and
hTERT-cHSF1/HSE promoters than with the CMV promoter
(Table 2) in all tissues, which were di⁄cult to di¡erentiate
from the basal expression from the pGL3-Basic vector alone.
The results indicate that the hTERT-cHSF1/HSE promoter
had no e¡ect on normal tissues in vivo and is suitable for
systemic administration.
4. Discussion
A major challenge facing the routine use of gene therapy in
the clinic is to achieve tumor-speci¢c treatment. Tumor tar-
geting can be accomplished at several levels, including direct
injection into a target site, vector targeting, and tissue-speci¢c
gene expression [19]. Intratumoral injection is appropriate for
the treatment of unresectable primary tumors, while systemic
gene delivery may be necessary for the treatment of metasta-
ses. However, systemic delivery of therapeutic genes induces
substantial toxicity to normal tissues, which suggests that ei-
ther targeting vectors or targeting gene transcription may be
essential for the systemic delivery of therapeutic genes in the
clinic. Targeting vectors were developed based upon non-viral
or viral gene delivery systems by various strategies [20], but
even using replicating vector, the e⁄ciency of gene delivery to
tumors is currently very low [1]. Therefore, an e⁄cient tran-
scriptional targeting system may give some compensation.
Use of tumor-selective gene promoters is an attractive op-
tion for transcriptional targeting. There is now a growing list
of tumor-speci¢c promoters that are generally active only in
the type of cancer from which they are derived or, at best, in a
very limited number of tumor types. In contrast, the hTERT
promoter should have the advantage of displaying activity
over a broad range of cancers of very di¡erent etiology which
augurs well for applications of hTERT promoter gene therapy
in a wide range of human malignancies. In this study, we
examined hTERT promoter-driven expression in cell lines
from liver, breast, cervical, and colonic cancers. We showed
that the hTERT promoter could drive gene expression specif-
ically in tumor cells but its activity was 10^30-fold less than
the CMV promoter. It is conceivable that expression of sui-
cide genes at a higher level is necessary for complete rejection
of tumors. To augment CD gene expression in tumor cells, we
applied the HSF1/HSE responsive system. cHSF1 was placed
downstream of the hTERT promoter. cHSF1 could transacti-
vate the tandem HSE element in the absence of stress. Lucif-
erase assay revealed that the hTERT-cHSF1/HSE promoter
could produce stronger luciferase gene expression than the
CMV promoter and its activity was strictly restricted to tumor
cells. Cytotoxic assay demonstrated that the CD gene under
the control of the hTERT-cHSF1/HSE promoter could selec-
tively kill tumor cells 23-fold more e⁄ciently than the hTERT
promoter and was comparable to the CMV promoter.
HSE is the promoter of the hsp70B gene. Hsp70 is known
to be abundantly expressed in human malignant tumors of
various origins. It makes tumor cells resistant to apoptosis,
which is especially deleterious because it not only enhances
the spontaneous growth of tumors but also renders them re-
sistant to host defense mechanisms as well as various forms of
therapy [14]. Cancer gene therapy using the hsp70B promoter
is considered to be tumor-speci¢c, as well as inducible [21]. In
our study, the hTERT-cHSF1/HSE promoter did not show
any leaking in normal cells tested, because the HSE element
in normal cells was not su⁄cient to initiate gene transcription.
Our experiments clearly demonstrate that the hTERT-cHSF1/
HSE promoter works at the transcriptional level and leads to
tumor-speci¢c cell killing comparable to that achieved with
the CMV promoter alone.
In addition to the greatly enhanced promoter activity, the
hTERT-cHSF1/HSE promoter could speci¢cally express
cHSF1 in tumor cells. cHSF1 expression could also transacti-
vate endogenous HSE elements upstream of cellular stress
response genes, such as hsp70. Previous studies have shown
that expression of cHSF in tumor cells induces expression of
hsp70 as well as other potentially immunostimulatory genes
[22,23], which is very important for in vivo gene therapy.
Induction of heat shock proteins is a highly potent immune
adjuvant to tumor cell killing [24] and leads to the generation
of long-term antitumor immunity.
To further study whether the enhancement of 5-FC sensi-
tivity in vitro is dependent on promoter activity only, or
cHSF1 itself may play a role, Ad-cHSF1 was used to infect
Bcap37/CMV-CD cells, for the CMV promoter activity is not
markedly in£uenced by heat shock [25]. IC50 data revealed
that cHSF1 overexpression could decrease the IC50 of
Bcap37/CMV-CD by 10 times. Fas-blocking antibody could
block this e¡ect. It has been demonstrated that the bystander
e¡ect of CD/5-FC gene therapy in vitro is mediated by 5-FU
[26] which induces apoptosis via the activation of the CD95/
CD95L system [18], so it may be the upregulation of Fas-
mediated apoptosis events in Ad-cHSF-infected cells that
was responsible for the decrease of IC50. Other studies also
found that Hsp70 overexpression could enhance Fas-mediated
cell death [27] and cHSF1 overexpression could sensitize tu-
mor cells to Fas killing [17]. Further studies about the inter-
play of Fas-mediated apoptosis with the (HSF1-activated)
stress response are needed.
Furthermore, the therapeutic e¡ect of the CD gene driven
Table 2
Activity of di¡erent promoters (hTERT, CMV, hTERT-cHSF1/HSE) in non-tumorous tissues
Liver Lung Heart Spleen Kidney
pGL3-Basic 3.31U102 T 89.8 1.53U102 T 26.8 2.79U102 T 89.4 2.11U102 T 68.7 3.04U102 T 1.21U102
CMV 8.69U105 T 3.65U104 6.21U104 T 7.24U103 4.28U104 T 7.62U103 7.12U104 T 2.10U104 2.56U105 T 9.15U104
hTERT 2.53U102 T 52.8 1.06U102 T 44.2 1.99U102 T 69.7 99.7T 15.6 3.48U102 T 90.3
hTERT-cHSF1/HSE 3.15U102 T 86.7 2.97U102 T 63.7 3.77U102 T 1.06U102 1.84U102 T 39.5 3.11U102 T 1.19U102
Luciferase reporter plasmid containing the luciferase gene under the control of di¡erent promoters (CMV, hTERT, hTERT-cHSF1/HSE) was
delivered to mice by the hydrodynamic procedure. Liver, lung, heart, spleen, and kidney were harvested 8 h after DNA infusion and luciferase
activity was determined in the organ extracts.
The values (meanTS.D.) are represented as relative light units of luciferase per mg of total cell proteins. Mice transfected with pGL3-Basic
without enhancer/promoter were used as a negative control. Much stronger luciferase activity was observed in each tissue tested after adminis-
tration of the luciferase gene driven by the CMV promoter compared with the other promoters (P6 0.01, n=4^6).
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by the hTERT-cHSF1/HSE promoter was explored in nude
mice. As expected, hTERT-cHSF1/HSE-CD led to substantial
suppression of tumor growth and was more e⁄cient than
CMV-CD. The following reasons may account for the en-
hancement of CD/5-FC gene therapy e⁄ciency by the
hTERT-cHSF1/HSE promoter in vivo: (1) it allows increasing
levels of CD to be expressed which will lead to very e¡ective
local tumor cell killing after 5-FC administration in vivo; (2)
it leads to tumor-speci¢c expression of cellular stress proteins,
including hsp70 and natural killer cell receptors which could
provide e¡ective adjuvant functions for immunostimulation in
vivo; and (3) it also enhances the bystander e¡ect of CD/5-FC
gene therapy by upregulating the Fas-mediated apoptosis
pathway. Besides high e⁄ciency for tumor gene therapy, the
hTERT-cHSF1/HSE promoter also retained strict speci¢city
for tumor tissues and was undetectable in normal tissues from
various organs when administered intravenously. Thus, with-
out the activation of the hTERT promoter in normal tissues,
transactivation of the HSE element by innate HSF1 was not
su⁄cient to initiate gene expression, so this promoter is prom-
ising in development of vectors for systemic administration.
In summary, we describe here a novel transcriptionally reg-
ulating promoter system which allows high level tumor-spe-
ci¢c expression of potent cytotoxic genes combined with an
inherent immunostimulatory capacity and an enhanced by-
stander e¡ect for e¡ective tumor-speci¢c gene therapy.
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